Alcon's stock has reset, improving risk-reward. See how sales growth, margin expansion, and innovation support its mid-term ...

Alcon has acquired Neurotech Pharmaceuticals for $550 million, expanding its retina portfolio with ENCELTO, the first and ...

Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

Alcon develops, manufactures and sells surgical and vision-care products worldwide, according to the company’s ...

GENEVA--FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes ...

The average one-year price target for Alcon Inc. - Depositary Receipt (BOVESPA:A2LC34) has been revised to R$43.42 / share. This is a decrease of 14.08% from the prior estimate of R$50.53 dated August ...

Alcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand. Click for more details on ALC.

Please provide your email address to receive an email when new articles are posted on . Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second half ...

Alcon has acquired Neurotech Pharmaceuticals and Encelto, its macular telangiectasia type 2 therapy, according to a press release.Alcon paid $550 million in the acquisition of Neurotech and could make ...

The US-based eye-care company is also developing intraocular lens products, while low adoption of premium cataract procedures ...

Alcon stock trades at EUR 62.78 in weekend trading on October 25, 2026. The next Xetra session is October 26, 2026. Alcon ...

Alcon has gained its first FDA nod for a prescription product since its 2019 split with Novartis, securing an approval for dry eye disease treatment Tryptyr. (Stock Photo ) Six years after being spun ...